Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for high unmet medical needs. The company's commercial portfolio includes Fanapt (iloperidone) for schizophrenia and bipolar I disorder, HETLIOZ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, PONVORY (ponesimod) for relapsing forms of multiple sclerosis, and NEREUS (tradipitant) for motion-induced vomiting. Vanda serves markets in the United States, Canada, Europe, and Israel. Its pipeline includes Bysanti (milsaperidone), Imsidolimab for generalized pustular psoriasis, VTR-297 for hematologic malignancies, and antisense oligonucleotides for rare genetic disorders. The company was incorporated in 2002 and commenced operations in 2003, with a history of strategic partnerships including a former sublicense agreement with Novartis for Fanapt rights.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage vandapharma.com
Sector Healthcare IR page vandapharma.com/investors
Tags
neurology, psychiatry, sleep disorders, multiple sclerosis, rare diseases, oncology, dermatology, genomics, antisense oligonucleotides, small molecules, Fanapt, HETLIOZ, PONVORY, NEREUS, Bysanti, Imsidolimab, VTR-297, VSJ-110, VPO-227, VQW-765, VCA-894A, VGT-1849A, iloperidone, tasimelteon, ponesimod, tradipitant, milsaperidone
Press page —

Metrics

Valuation  
Market cap $ 230.037M
Market cap (USD) $ 230.037M
P/E -0.82
PEG —
P/BV 1.15
P/S 1.00
P/OCF -1.65
P/FCF -1.64
Dividend yield —
Turnover / mcap —
Returns  
ROE -50.9%
ROI -89.5%
ROIC -46.0%
Profit margin -102.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 17
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 216.105M 198.772M 192.64M 254.382M 268.682M 248.168M 227.188M 193.118M 165.083M 146.017M 109.925M 50.157M 33.879M 32.727M 31.27M 35.709M 4.548M — — —
Net profit -220.474M -18.9M 2.509M 6.275M 33.152M 23.337M 115.553M 25.208M -15.567M -18.01M -39.865M 20.186M -20.255M -27.664M -9.802M 7.192M -35.859M — — —
Free cash flow -110.44M -16.247M 12.418M 31.305M 63.662M 49.98M 44.928M 29.618M -3.647M -9.51M 9.922M -82.323M -39.768M -46.934M -28.685M — 169.336M — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 8.82 4.79 4.22 7.39 15.69 13.14 16.41 26.13 15.2 15.95 9.31 14.32 12.41 4.05 5.99 8.1 11.65 0.73 9 25.39
Price performance 12m 0.84 0.14 -0.43 -0.53 0.19 -0.2 -0.37 0.72 -0.05 0.71 -0.35 0.15 2.06 -0.32 -0.26 -0.3 14.96 -0.92 -0.65 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 20.3M 17.6M 28.8M 26.4M 30M 32.5M 33.5M 34.2M 47.1M 54.6M
↳ YoY growth +24.1% -13.2% +63.5% -8.4% +13.9% +8.1% +3.2% +1.9% +37.9% +15.9%
↳ 5y CAGR +65.8% +72.0% +69.9% +48.5% +13.0% +9.9% +13.7% +3.5% +12.3% +12.7%
Lease liabilities (USD) — — 0.00 14.6M 13.6M 12.4M 11.1M 9.4M 12.4M 12.6M
Cash and deposits (USD) 40.4M 33.6M 61M 45.1M 61M 52.1M 135M 136M 102M 84.9M
Intangible assets (USD) 27.8M 26.1M 24.5M 23M 21.6M 20.1M 18.6M 121M 114M 117M
Right-of-use assets (USD) — — 0.00 11.2M 10.5M 9.27M 8.4M 7.1M 5.6M 3.92M
Cash flow detail
Operating cash flow (USD) -8.1M -1.98M 30M 45.9M 51.8M 64.2M 32M 12.8M -15.8M -109M
Purchases of property, plant and equipment (USD) -1.41M -1.66M -368,000 -1.02M -1.8M -552,000 -679,000 -383,000 -490,000 -998,000
Purchases of intangible assets (USD) 0.00 0.00 -25M 0.00 0.00 — — — — —
Change in receivables (cash effect) (USD) -4.3M 2.53M -11.2M 2.34M -3.77M -2.47M -1.09M -707,000 -13M -7.46M
Change in inventories (cash effect) (USD) 200,000 -1.06M 70,000 -722,000 -2.88M -2.23M -4.48M -771,000 -29,000 -3.47M
Change in payables (cash effect) (USD) 575,000 5.95M -618,000 3.51M 3.76M 3.04M 11.8M -11M 1.71M 15.8M
Income taxes paid (cash effect) (USD) — — — — — 0.00 0.00 -3.6M -2.4M 90,000
Share-based compensation (USD) 8.54M 10.5M 11.7M 13.5M 13.4M 15.4M 16.3M 14M 12.4M 9.47M
Operating cash flow before change in receivables (USD) -3.81M -4.51M 41.2M 43.6M 55.5M 66.7M 33.1M 13.5M -2.75M -102M
Free cash flow (OCF - PPE - intangibles) (USD) -9.51M -3.65M 4.62M 44.9M 50M 63.7M 31.3M 12.4M -16.2M -110M
Income detail
Research and development expense (USD) 29.2M 38.5M 43.6M 48.6M 55.6M 75.4M 85.8M 76.8M 74.4M 109M
↳ 5y CAGR +0.1% -3.2% +9.1% +20.4% +13.8% +20.9% +17.3% +12.0% +8.9% +14.5%
Total comprehensive income (USD) -18M -15.7M 25.2M 116M 23.3M 32.7M 5.26M 3.67M -18.8M -220M
Comprehensive income to owners (USD) -18M -15.7M 25.2M 116M 23.3M 32.7M 5.26M 3.67M -18.8M -220M
Reported Feb 19, 2019 Feb 19, 2019 May 3, 2019 Feb 26, 2020 Feb 11, 2021 Feb 8, 2024 Feb 8, 2024 Feb 8, 2024 Feb 14, 2025 Feb 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026

•Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026

•Announced positive results from the Phase III study of NEREUS™ for prevention of GLP-1-induced vomiting

•NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026

•BYSANTITM commercial launch expected in Q4 2026

•QuimilzaTM BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026

WASHINGTON – October 28, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026.

“We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude,” said Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board.

•Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%

•Full-year 2026 total revenue guidance of $240-$290 million

•Cash totaled $170.0 million as of June 30, 2026; expected to fund operations through at least the end of 2027

•BYSANTITM (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026

•QuimilzaTM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026

•NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026

•Results for three Phase III clinical trials expected by end of 2026:

◦NEREUS™ (tradipitant) in vomiting in GLP-1,

◦VQW-765 in social anxiety disorder

◦HETLIOZ® (tasimelteon) in delayed sleep phase disorder

WASHINGTON – August 5, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026.

“We are pleased with the continued strong growth of Fanapt and the enthusiastic early response to NEREUS as it becomes available to patients.

At the 2026 annual meeting of stockholders of Vanda Pharmaceuticals Inc. (the “Company”) held on June 4, 2026 (the “Annual Meeting”), the following proposals were submitted to the stockholders of the Company: Proposal 1: The election of three directors to serve as Class II directors for a term of three years until the Company’s 2029 annual meeting of stockholders. Proposal 2: The ratification of the selection, by the Audit Committee of the Company’s Board of Directors (the “Board”), of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Proposal 3: The approval on an advisory, non-binding basis of the compensation of the Company’s named executive officers. Proposal 4: The approval of an amendment to the Company’s Amended and Restated 2016 Equity Incentive Plan, as amended (the “2016 Plan”), to increase the aggregate number of shares authorized for issuance thereunder. For more information about the foregoing proposals, see the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2026 (the “Proxy Statement”).

Prompts

Vanda Pharmaceuticals Inc. (ticker VNDA), listed in United States.

ETFs Holding Vanda Pharmaceuticals Inc.

ETF Weight in ETF Shares Market value As of
MEDX 0.73% 22,648 $ 138.606K Jun 30, 2026
FSCC 0.20% 133,947 $ 723.314K Aug 31, 2026
SQLV 0.15% 6,814 $ 41.702K Jun 30, 2026
VFMF 0.04% 80,810 $ 436.374K Aug 31, 2026
FSEV 0.04% 417 $ 2,552.04 Jun 30, 2026
VFQY 0.03% 28,560 $ 154.224K Aug 31, 2026
AVSC 0.02% 134,435 $ 512.197K Nov 16, 2026
RESM 0.01% 66 $ 403.92 Jun 30, 2026
FESM 0.01% 62,382 $ 381.778K Jun 30, 2026
DFSV 0.01% 397,304 $ 1.569M Nov 12, 2026
DFAS 0.01% 445,339 $ 1.759M Nov 12, 2026
DXUV 0.00% 22,721 $ 89.748K Nov 12, 2026
DFAC 0.00% 287,173 $ 1.134M Nov 12, 2026
DCOR 0.00% 69,909 $ 276.141K Nov 12, 2026
DFAU 0.00% 10,453 $ 41.289K Nov 12, 2026
DFUS 0.00% 12,885 $ 50.896K Nov 12, 2026
AVUS 0.00% 11,217 $ 42.737K Nov 16, 2026
AVSU 0.00% 1,556 $ 5,928.36 Nov 16, 2026